Statyny u chorych dializowanych otrzewnowo — za i przeciw

Abstract

HMG-CoA reductase inhibitors (statins) have proven their efficacy in improving the prognosis of patients with increased cardio-vascular risk. This risk is specif­ically high in end-stage renal failure patients undergo­ing peritoneal dialysis (PD). Moreover, these patients are characterized by atherogenic lipid disturbances, caused by the kidney disease itself as well as the glu­cose load from dialysis fluids. Therefore, stains ought to constitute a perfect group of drugs in reducing the cardio-vascular risk in PD subjects. However, results of the hitherto studies are far from being unequivocal in this respect. Moreover, the current guidelines do not recommend initializing statins in PD patients. This ar­ticle aims at presenting the current knowledge on the use of these drugs in the course of PD.